Last reviewed · How we verify

NCT03660371

ILM Peeling in PDR Patients Undergoing PPV for VH

Completed NA Last updated 2 December 2021
What this trial tests

NA trial testing PPV/MP in Diabetic Retinopathy in 258 participants. Completed in 4 March 2020.

Timeline
4 September 2018
Primary endpoint
4 March 2020
4 March 2020

Quick facts

Lead sponsorRush Eye Associates
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment258
Start date4 September 2018
Primary completion4 March 2020
Estimated completion4 March 2020
Sites1 location across Mexico

Drugs / interventions tested

Conditions studied

Sponsor

Rush Eye Associates

Who can join

Adults 18 to 85, any sex, with Diabetic Retinopathy or Macular Edema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Subjects undergoing ILM peeling during vitrectomy will have better visual acuity and lower rates of DME to control subjects

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of PPV/MP

Trials testing the same drug.

Other recruiting trials for Diabetic Retinopathy

Currently open trials in the same condition.

Other Rush Eye Associates trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03660371.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing